UNIVERSAL INTEGRATION VECTOR pVEAL AND RECOMBINANT PLASMID pVEAL-15742, PROVIDING SYNTHESIS AND SECRETION OF scFv-Fc ANTIBODIES AGAINST EBOLA VIRUS ADI-15742 IN MAMMALIAN CELLS AND OBTAINED USING pVEAL VECTOR Russian patent published in 2021 - IPC C12N15/63 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology. Described is the universal integration vector pVEAL and the recombinant plasmid pVEAL-15742, which provides the synthesis and secretion of scFv-Fc antibodies ADI-15742 capable of neutralizing the Ebola virus in mammalian cells. The universal integration vector pVEAL is used to create target plasmid constructs that provide for the synthesis and secretion of scFv-Fc monoclonal antibodies, has the nucleotide sequence SEQ ID No. 1 and contains elements in accordance with the physical and genetic map shown in Fig. 1. The plasmid genetic construct pVEAL-15742, which provides the synthesis and secretion of the target protein scFv-Fc of the anti-Ebola virus ADI 15742 antibody, has the nucleotide sequence of SEQ ID No. 2 and contains elements in accordance with the physical and genetic map shown in Fig. 2.

EFFECT: creation of a universal integration vector pVEAL and a plasmid genetic construct pVEAL-15742, which provides the synthesis and secretion of the target protein scFv-Fc of the ADI 15742 antibody against the Ebola virus in mammalian CHO-K1 cells, obtained using the specified universal vector pVEAL.

2 cl, 6 dwg, 5 ex